Body fat distribution and inflammation may play a role in metabolic derangements and cardiovascular disease in obesity.
O
besity is a well-recognized risk factor for metabolic syndrome and atherosclerotic cardiovascular disease (1) . However, the association of obesity with cardiometabolic diseases is not consistently observed in humans (2) . Whereas some obese individuals develop insulin resistance, type 2 diabetes, and nonalcoholic fatty liver disease, others are protected against these metabolic disorders (3) . Body fat distribution could partly explain the phenomenon (4) . Indeed, accumulation of visceral fat is more harmful than that of sc fat (4, 5) . There is growing evidence that increased visceral fat volume is positively associated with disturbed adipocytokine profiles, various metabolic derangements, and atherosclerotic cardiovascular disease, independent of overall adiposity (6, 7) . Furthermore, macrophage infiltration and chronic inflammation in the adipose tissues have also been shown to be associated with the metabolic alterations (8, 9) . Because visceral and sc adipose tissues (VAT and SAT) have different gene expression profiles (10) , it is conceivable that inflammation in each adipose tissue could have different implications in the risk of metabolic disorders and atherosclerotic cardiovascular disease, which might provide another possible explanation why some obese subjects have favorable metabolic profiles, whereas others have deleterious ones. Therefore, although most clinical studies have focused on volumetric quantification of VAT and SAT by computed tomography (CT) (4, 5) , simultaneous assessment of inflammation in two distinct adipose tissues may also be of importance for distinguishing metabolically healthy obesity from unhealthy obesity. However, a potential problem for evaluating the inflammation in each adipose tissue is that it is measurable only with invasive adipose tissue biopsy.
In this regard, we, along with others, have recently demonstrated that 18 F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) combined with CT imaging allows the assessment of glucose metabolic activity and inflammation in the adipose tissues (11, 12) . Moreover, we have found that pioglitazone, a peroxisome proliferator-activated receptor-␥ agonist with an insulin-sensitizing property, reduces area and metabolic activity in VAT but not SAT of patients with impaired glucose tolerance or type 2 diabetes mellitus (12) . These observations suggest that area and metabolic activity in the VAT and SAT might be differentially regulated and that FDG-PET/CT imaging could be a reliable tool for evaluating these two parameters separately.
In the present study, using FDG-PET/CT imaging, we examined which clinical and biochemical factors, including serum levels of advanced glycation end products (AGEs), pigment epithelium-derived factor (PEDF), and adiponectin, were independently associated with area and metabolic activity in VAT and SAT because we have previously found that AGEs, senescent macroprotein derivatives formed at an accelerated rate under hyperglycemic and/or oxidative stress conditions, contribute to the decrease in adiponectin expression as well as the increase in adipocyte size of VAT in fructose-fed rats (13) and that PEDF, a glycoprotein that belongs to the superfamily of serine protease inhibitors with antiinflammatory properties, could restore the adiponectin level and suppress macrophage infiltration into the VAT of obese type 2 diabetic animals partly by blocking the harmful effects of AGEs (14) .
Subjects and Methods

Study design and subjects
A total of 251 consecutive subjects (172 males and 79 females), who visited our hospital for risk-screening tests of cardiovascular disease, underwent a physical examination, blood analysis, carotid artery ultrasonography, and FDG-PET/CT. We excluded any patients who had uncontrolled diabetes [fasting plasma glucose (FPG) Ն 200 mg/dL]; were undergoing insulin treatment; were taking systemic steroids or biological agents; had symptomatic coronary artery disease (CAD) or cerebrovascular disease within the past 6 months at enrollment; or had vasculitis, collagen disease, acute infection, or malignancy. Written informed consent was obtained from all subjects. Cerebrovascular disease or CAD was historically diagnosed in the present study. The research protocol was reviewed and approved by the Ethical Committee for Clinical Research of Kurume University and approved this study. The trial was duly registered with Clinical Trial Registration (number NCT00722631).
Data collection
The medical history, smoking habit, and drug use were ascertained by questionnaire. Weight and height were measured to calculate body mass index (BMI; kilograms per meter squared). Waist circumference was measured at the umbilical level in the late exhalation phase. After at least a 5-minute rest, blood pressure (BP) was measured in the supine position using a standard sphygmomanometer. Vigorous physical activity and smoking were avoided for at least 30 minutes before resting BP and heart rate measurements.
After an overnight fast, peripheral blood was drawn from the antecubital vein for measurements of lipid profiles, liver function markers [aspartate aminotransferase, alanine aminotransferase (ALT), alkaline phosphatase and ␥-glutamyl transpeptidase (␥-GTP)[, glycemic parameters [FPG, fasting immunoreactive insulin (IRI), and glycated hemoglobin (HbA1c)[, creatinine, uric acid, high-sensitivity C-reactive protein (hsCRP), and total adiponectin. These chemistries were measured at a commercially available laboratory (The Kyodo Igaku Laboratory, Fukuoka, Japan) as described previously (12, 15, 16) .
Insulin resistance was estimated using the homeostasis model assessment of insulin resistance (HOMA-IR) from FPG and IRI concentrations using the following formula: HOMA-IR ϭ [fasting IRI (microunits per milliliter) ϫ FPG (milligrams per deciliter)]/405. Estimation of glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease study equation modified with a Japanese coefficient (17) . The value for HbA1c (percentage) is estimated as a National Glycohemoglobin Standardization Program equivalent value (percentage) calculated by the following formula: HbA1c (National Glycohemoglobin Standardization Program) (percentage) ϭ 1.02 ϫ HbA1c (Japan Diabetes Society) (percentage) ϩ 0.25% (18) .
Measurement of serum AGE level was performed with a competitive ELISA as described previously (16, 19) . In brief, 96-well microtiter plates were coated with 0.1 g/mL AGE-BSA. Then test samples (50 L) were added to each well as a competitor for 50 L of polyclonal antibodies directed against AGE-BSA (1: 1000), followed by incubation for 2 hour at room temperature with gentle shaking on a horizontal rotary shaker. After incubating each well with alkaline phosphatase-conjugated antirabbit IgG, p-nitrophenyl phosphate was added as a colorimetric substrate. Then the plate was read using a microplate reader. In this study, 1 U corresponds to 1 g of glyceraldehyde-derived AGE-BSA standard. Intra-and interassay coefficients of variation were 6.2% and 8.8%, respectively.
The PEDF level was determined with an ELISA system (20) . Inter-and intraassay coefficients of variation of the ELISA were 4.7% and 7.3%, respectively (20) .
Carotid intima-media thickness
The intima-media thickness (IMT) of the common carotid artery was determined using duplex ultrasonography (SSA-380A; Toshiba) with a 10-MHz transducer. Longitudinal B-mode images at the diastolic phase of the cardiac cycle were recorded by a single trained technician who was blinded to the subjects' background. The images were magnified and printed using a high-resolution line recorder (LSR-100A; Toshiba). Measurements of carotid IMT were made by the same technician using fine slide calipers at three levels of the lateral and medial walls 1-3 cm proximal to the carotid bifurcation as described previously (15, 16) . The mean of these six measurements was taken as the value for the carotid IMT (15, 16) . The intraobserver or interobserver variability of IMT measurements was less than 5%.
Adipose tissue imaging
Adipose tissue imaging was performed by a hybrid PET/CT after at least 12 hours of fasting as described previously (12) . In brief, the enrollees received an iv administration of FDG [4.2 MBq (0.12 mCi/kg) body weight] through the antecubital vein. One hour after the FDG injection, three-dimensional, wholebody PET imaging was carried out using an integrated full-ring PET and a 16-slice multidetector CT scanner (Gemini-GXL 16; Philips Medical Systems, Inc). A noncontrast full-dose CT scan was acquired starting from the level of the head using the following parameters: for a tube voltage of 120 kV, 0.75 sec/tube rotation with a tube current of 200 mA, slice thickness of 4.0 mm without breath holding. The noncontrast CT data were used for attenuation correction and localization. After both the transmission and emission images were obtained, images were reconstructed using the three-dimensional line-of-response row-action maximum likelihood algorithm (3D-LOR-RAMLA; Philips). The CT dose index and the dose-length product were 35.0 mGy and 314.7 mGy/cm for each CT scan, respectively.
Area in the VAT and SAT
Area in the VAT and SAT was estimated by calculating VAT and SAT areas using a standardized method with CT scan and Fat Scan software (N2 System Corp). Detailed information on the methods of measurement of VAT and SAT areas and activities was previously published (12) . In brief, a region of interest (ROI) of the fat layer was defined by tracing its contour on each scan, and the attenuation range of CT numbers in Hounsfield units for adipose tissue was calculated. The pixels with attenuation values in the selected attenuation range were depicted. From the regions, the total adipose tissue area was calculated by counting the number of pixels in each; the VAT area was subtracted, and the remainder was defined as the SAT area. The adipose tissue area was determined as the average of areas at the umbilical level and the additional 10 levels separated by 4 mm in length in top and bottom from the umbilical level obtained from consecutive CT images (total slices: 11) (12). The investigators who performed the measurements of adipose tissue were blinded to the patients' characteristics.
Metabolic activity in the VAT and SAT
Metabolic activity in the VAT and SAT was assessed by FDG-PET and CT scan as described previously (12) . ImageJ software (National Institutes of Health, Bethesda, Maryland) was used for image analysis. We created a fat mask image from the original CT image and a resampled PET image from the original PET image set by corresponding to adipose area slices in patients and then combined them to accomplish a PET fat mask image on a workstation (12) . We drew ROIs in each contour of VAT and SAT in consecutive levels and evaluated as follows. The intensity of FDG uptake was quantified by measuring the maximum standardized uptake value (SUV) corrected for body weight, injected FDG dose, and ROI volume. Subsequently the FDG uptake on the adipose tissues was corrected for blood activity by dividing by maximum venous blood SUV to produce a blood-corrected glucose metabolism; as known target to background ratio (TBR; maximum adipose tissue SUV/maximum venous blood SUV). We then averaged TBR values from 11 levels to obtain a TBR score in both VAT and SAT regions. Two blinded radiologists measured the area and FDG uptake on the two distinct adipose tissues. The intraobserver or interobserver variability of these measurements was less than 5%.
Statistical analysis
Data were described presented as mean values Ϯ SD or medians with the interquartile range. We performed the ShapiroWilk test to evaluate the assumption of normality. Statistical analysis was performed by means of appropriate parametric and nonparametric methods. Discontinuous variables were coded as binary dummy variables. Correlations between area and TBR in the VAT and SAT and other clinical variables were determined by a linear regression analysis. To determine independent parameters associated with area and metabolic activity in the VAT and SAT, a backward multiple stepwise regression analysis was performed. Statistical significance was defined as P Ͻ .05. All statistical analyses were performed with the use of the SPSS system (SPSS Inc).
Results
Demographical data of the subjects are presented in Table  1 . The age of enrolled subjects ranged from 38 to 83 years with a mean age of 62.6 Ϯ 9.3 years. AGEs, areas, and TBRs in the VAT and SAT were normally distributed, but PEDF was not. There were no significant differences in age, BP, aspartate aminotransferase, triglycerides, lowdensity lipoprotein (LDL)-cholesterol, fasting IRI, HOMA-IR, HbA1c, estimated GFR, and hsCRP between genders. BMI and waist circumference in males were significantly higher than those in females. Serum levels of AGEs and PEDF were 9.81 Ϯ 3.21 U/mL and 14.0 (range 10.8 -17.7) g/mL, respectively. Serum levels of PEDF were significant higher in males than in females, whereas AGEs were comparable between genders. Male predominance was observed in patients who were active smokers, had cardiovascular disease, and were taking aspirin or medication for diabetes. The VAT area was significant higher in males than in females, whereas the SAT area was significant higher in females than in males. VAT exhibited a significantly higher TBR value than SAT (0.49 Ϯ 0.10 vs 0.27 Ϯ 0.06, P Ͻ .001). The TBR value in the SAT was significant higher in males than in females. On the other hand, the TBR value in the VAT was similar between genders.
Statistical significant factors associated with VAT and SAT areas and TBRs are shown in Table 2 (for VAT) and Table 3 (for SAT). In univariate analyses, being male, BMI, waist circumference, systolic and diastolic BP, ALT, ␥-GTP, triglycerides, high-density lipoprotein (HDL)- cholesterol (inversely), FPG, fasting plasma insulin, HOMA-IR, uric acids, AGEs, PEDF, adiponectin (inversely), and active smoking were correlated with VAT area, whereas diastolic BP (inversely), FPG, HbA1c, AGEs, CAD, and use of aspirin and medications for hypertension and diabetes with were correlated VAT TBR (Table 2) . Because these significant parameters could be closely correlated with each other, we performed backward multiple stepwise regression analyses to determine independent correlates of VAT area and TBR. Multiple regression analyses revealed that waist circumference (P Ͻ .001), male (P Ͻ .001), ␥-GTP (P Ͻ .003), diastolic BP (P Ͻ .002), and HOMA-IR (P Ͻ .05) were independently associated with VAT area (R 2 ϭ 0.597). AGEs (P Ͻ .003) and medication for hypertension (P Ͻ .002) remained significant and were independently correlated with visceral fat TBR (R 2 ϭ 0.102). Furthermore, as shown in Table 3 , waist circumference (P Ͻ .001) and female (P Ͻ .001) were independent correlates of SAT area (R 2 ϭ 0.552), whereas AGEs (P Ͻ .03), PEDF (P Ͻ .001), mean carotid IMT (P Ͻ .02), and medication for diabetes (P Ͻ .05) were independently associated with SAT TBR (R 2 ϭ 0.132). When we analyzed the data of males and females separately, in addition to waist circumference, ␥-GTP and ALT were independently associated with VAT and SAT areas in males, respectively, whereas CAD was independently associated with SAT area in females (Supplemental Table 1 ). Medications for hypertension and diabetes in males and AGEs in females were independently correlated with TBR in the VAT (Supplemental Table 2 ). Furthermore, medication for diabetes was an independent correlate of TBR in the SAT in males, whereas AGEs and carotid IMT were independently correlated with the SAT TBR in females (Supplemental Table 2 ).
Discussion
We found here for the first time that area and metabolic activity in VAT and SAT have different metabolic risk profiles. In the present study, male gender, waist circumference, diastolic BP, and HOMA-IR were correlated with VAT area, which was totally consistent with previous findings showing that classical cardiovascular risk factors such as hypertension and hyperglycemia were independent correlates of visceral obesity evaluated by CT (4, 5). Furthermore, several clinical studies have shown that serum level of ␥-GTP is elevated in patients with visceral obesity and could be a biomarker of nonalcoholic fatty liver disease, a hepatic manifestation of metabolic syndrome (21, 22) . Therefore, the positive and independent association of ␥-GTP with visceral fat volume observed here could further support the active participation of vis- ceral adiposity in the pathogenesis of nonalcoholic fatty liver disease. In contrast to the case of VAT area, we found that classical risk factors were not independently correlated with VAT TBR, a marker of metabolic activity and inflammation in the adipose tissues (12) . In this study, circulating level of AGEs and medication for hypertension were independent correlates of VAT TBR. We, along with others, have shown the following: 1) AGEs evoke inflammatory and oxidative stress reactions in various types of cells, including cultured adipocytes; 2) AGEs accumulate in the VAT of animal model with obesity, which could stimulate macrophage infiltration and inflammatory reactions in the visceral fat, thereby evoking insulin resistance; 3) circulating AGEs level is an independent biomarker of insulin resistance in nondiabetic subjects; and 4) serum level of AGEs is independently associated with vascular inflammation evaluated by FDG-PET/CT (13, 16, (23) (24) (25) (26) (27) . FDG accumulation corresponds to macrophagerich areas of carotid plaques and could reflect focal inflammation (28) . Given the pathological role of macrophage infiltration and inflammation in VAT in metabolic derangements and atherosclerotic cardiovascular disease (25) , AGEs might cause metabolic derangements and insulin resistance partly by evoking inflammatory reactions in the VAT. Our present study suggests that circulating AGEs might be a biomarker that could reflect the metabolic activity and inflammation in the VAT. We also found that medication for hypertension was independently associated with the VAT TBR. VAT metabolic activity might play a role in endothelial dysfunction and obesity-related hypertension.
In the present study, waist circumference and female gender were independently associated with the SAT area, which was also consistent with previous reports (4, 5) . However, we found here that metabolic activity in VAT was higher than that in SAT, and although circulating AGEs level was independently correlated with SAT TBR as the case in VAT TBR, VAT and SAT metabolic activities had different metabolic risk profiles. In this study, in addition to medication for diabetes, the serum level of PEDF and carotid IMT were independent correlates of SAT TBR. We have previously shown the following: 1) PEDF blocks the harmful effects of AGEs on adipocytes and ameliorates insulin resistance in vitro, 2) PEDF improves dysregulation of adiponectin expression and suppresses inflammatory reactions and macrophage infiltration in VAT of obese type 2 diabetic animal, 3) AGEs stimulate PEDF expression in adipocytes, and 4) circulating level of AGEs is independently correlated with PEDF in a general population (14, 29, 30 ). These observations suggest that PEDF may be elevated in response to circulating AGEs as a countersystem against the AGE-elicited SAT inflammation. We have reported that serum level of PEDF is independently associated with carotid IMT and vascular inflammation evaluated by FDG-PET in humans (31) . Therefore, the independent association of carotid IMT with sc fat TBR observed here suggests that AGE-evoked inflammation in SAT may also contribute to atherogenesis, whose process could be counterbalanced by PEDF. Recently SAT inflammation is associated with fatty liver and insulin resistance in obesity, further supporting the concept that SAT inflammation could play a pathological role in metabolic derangements and atherosclerosis (32, 33) .
There are some limitations in the present study. This study was cross-sectional and therefore did not elucidate the causal relationships among adipose tissue area and metabolic activity and other clinical biomarkers in humans. Furthermore, due to ethical issues, we could not obtain adipose tissue samples from our patients. Hence, we could not actually confirm that FDG uptake represents the inflammatory activity in adipose tissues and did not know which type of cells in the adipose tissues could be mainly involved in FDG uptake. Moreover, although vascular TBR has been shown to correlate with the density of macrophage infiltration of the vessel (28) and cardiovascular events (32) , the clinical significance of TBR in VAT and SAT is far less clear, particularly because the TBR may reflect either glucose uptake by fat cells or glucose uptake by infiltrating inflammatory cells. With regard to the issue, we examined whether TBR in the VAT and SAT related to TBR in the carotid and ascending aorta. We found here that either carotid or aortic TBR was not associated with TBR in the VAT and SAT (data not shown). In addition, due to a lack of contrast CT images, we could not analyze the correlation of TBR in the VAT and SAT with plaque or vulnerable plaque in the carotid, ascending aorta, or coronaries. Therefore, although SAT TBR related weakly to carotid IMT, a surrogate of cardiovascular risk in the present study, it is important to study further the relationship between more powerful imaging surrogates of cardiovascular risk and TBR in the VAT and SAT. We had studied the SUV values that measured FDG concentrations but not necessarily uptake in cells. This uptake would need dynamic collection of PET data and modeling.
The adipose tissue areas can vary considerably due to change of organ position during breath and intestinal movement in the abdominal cavity. Furthermore, in the whole-body CT scan, imaging was not acquired only in the late exhalation phase, so we could not accurately measure the VAT and SAT areas or volumes covering the whole abdomen. This is a reason that we measured the averaged areas of relatively small region (11 slices centered at the umbilical level, span of area studies was 4.4 cm) in the present study. The manual analysis (ie, subjective) and the use of two operators were also listed as limitations.
The multiple regression coefficient (R 2 ) for TBR in the VAT and SAT revealed approximately 0.10 (Tables 2 and  3 ). Many other factors not evaluated in this study could affect the metabolic activity in VAT and SAT. Moreover, we could not totally exclude the possibility that comedication may affect the present results because both serum levels of AGEs and PEDF may be influenced by medications for diabetes, hypertension, or statins (34 -38) . The characterization of AGEs measured is important to interpret the present data. In this study, we measured glyceraldehyde-derived AGEs to examine the relationship between AGEs and adipose tissue area and TBR because we previously found that serum levels of glyceraldehyde-derived AGEs were elevated under inflammatory conditions and correlated with vascular inflammation evaluated by FDG-PET (16) and that they were inversely associated with adiponectin, an adipocytokine with antiinflammatory and insulin-sensitizing properties in patients with nonalcoholic fatty liver disease (39) . Therefore, although modification of proteins with glyceraldehyde could generate a large number of structurally unidentified AGEs, our present study might suggest the clinical utility of measurement of serum levels of glyceraldehyde-derived AGEs for evaluating VAT and SAT inflammation in humans. We previously reported that antibodies raised against glyceraldehyde-derived AGEs used for the ELISA did not cross-react with early glycation products (HbA1c and/or fructoselysine) or structurally identified AGEs such as glyoxal and methylglyoxal hydroimidazolones, carboxymethyllysine, carboxyethyllysine, or pentosidine (16) . These structurally identified AGEs were not evaluated in our ELISA system. In this study, there was no significant association of adiponectin with TBR in the VAT and SAT. We did not know the exact reason for the lack of association. AGEs or PEDF might be more upstream regulators of TBR in the VAT and SAT than adiponectin. Further longitudinal interventional study is needed to clarify the clinical utility of measuring this type of AGEs and PEDF for evaluating VAT and SAT metabolic activity and predicting future cardiovascular events in humans.
